Abramson Cancer Center bone marrow and stem cell transplant clinicians and researchers have led the way nationally for years; both in the care of patients undergoing transplant and in its research.
Today, there's more hope than ever for those who face a cancer diagnosis in which bone marrow or stem cell transplant is a treatment option.
Penn's program is one of the oldest and largest in the country. By putting our experience to work, we offer the best possible treatment outcomes.
Bone Marrow Transplant is a procedure to replace bone marrow that has been destroyed by treatment with high doses of anticancer drugs or radiation.
Transplantation may be autologous (an individual's own marrow saved before treatment), allogeneic (marrow donated by someone else), or syngeneic (marrow donated by an identical twin).
Stem Cell Transplant is a method of replacing immature blood-forming cells that were destroyed by cancer treatment. The stem cells are given to the person after cancer treatment to help the bone marrow recover and continue producing healthy blood cells.
If bone marrow or stem cell transplant is a treatment option for you, it's important to have the best team of experts available.
At Penn's Bone Marrow and Stem Cell Transplant Program you'll find individuals nationally recognized for their expertise. They can provide the information, care and support to help you each step of the way.
Penn has one of the few Hematologic Malignancy (leukemia, lymphoma and myeloma) Research Programs in the country that is approved and funded by the National Cancer Institute. It is through this research program that Penn has made significant advances in improving bone marrow and stem cell transplants.
The knowledge gained through our research allows us to better care for those undergoing bone marrow/stem cell transplant.
To learn about what sets us apart, visit:
Nicholas Martell was first diagnosed with prostate cancer more than ten years ago. He was healthy for many years after being treated with radiation therapy. Nick recently experienced a recurrence of his cancer. Physicians at Penn tailored his treatment and enrolled him in a new Phase I clinical trial using laser-based photodynamic therapy (PDT) followed by hormone therapy. This leading edge treatment plan was effective. Nick just returned from a vacation with his daughter, and in his free time, he plays golf every chance he gets.